Cita APA

Kanevsky, D., Elgart, J. F., Zerga, M., Glancszpigel, M., & Morisset, P. (2022). Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis. Web

Citación estilo Chicago

Kanevsky, Diego, Jorge Federico Elgart, Marta Zerga, Mariana Glancszpigel, and Pierre Morisset. Venetoclax in Combination With Obinutuzumab in First Line Chronic Lymphocytic Leukemia in Argentina: A Cost-effectiveness Analysis. 2022.

Cita MLA

Kanevsky, Diego, et al. Venetoclax in Combination With Obinutuzumab in First Line Chronic Lymphocytic Leukemia in Argentina: A Cost-effectiveness Analysis. 2022.